Skip to main content
. 2023 Jul 26;39:100847. doi: 10.1016/j.lanwpc.2023.100847

Table 11.

Analysis of serum anti-palivizumab antibodies (FAS).

Time point Category (N = 23)
n (%)
30 days after the fourth dose <30 22 (95.65)
30 days after the fifth dose <30 2 (8.70)

FAS, full analysis set. Data are shown in [μg/mL] unless otherwise stated.